Show simple item record

dc.contributor.advisorMatherly, Larry H.
dc.contributor.authorBark, Kenneth S.
dc.descriptionvii, 24 p.en_US
dc.description.abstractThe reduced folate carrier (RFC) is important for cancer patients because it is responsible for the uptake of antifolate drugs like methotrexate (MTX) which causes cell and tumor death. It is known that defective antifolate uptake is caused by alterations in the RFC gene, and two mutations have been found: a glutatmate to lysine substitution at amino acid position 45 (Glu-Lys45) and an arginine to histidine substitution at amino acid position 27 (Arg-His27). The Arg-His27 mutation causes the appearance of a restriction site for the enzyme DraIII, and the Glu-Lys45 mutation causes the disappearance of a BanI restriction enzyme cutting site. The region encompassing the RFC gene of human genomic DNA of a random population were amplified by polymerase chain reaction (PCR). These amplifications were then subjected to restriction digests, one by DrallI and another by BanI. A polymorphism can be defined as a difference in DNA sequence among individuals. Genetic variations occurring in more than 1% of a population are considered to be polymorphisms. From the 35 patients screened with the Dram digestions, an allele frequency of 60% for the wildtype allele and 40% for the mutant allele was determined, and therefore, the Arg-His27 mutation can be considered to be a polymorphism. The BanI digestions for the Glu-Lys45 mutation provided inconclusive evidence. However, through the sequencing of certain patients it was discovered that another BanI cutting site alteration exists on the RFC gene. An amino acid substitution seems to occur in one of the patients at position 3 in which a leucine substitutes a proline (Pro-Leu3). Because proline is commonly known as a helix breaker, the discovery of this polymorphism may be a lead into changes in structure and function of the RFC protein. Via the determined polymorphism of the Arg-His27 and the discovery of other possible polymorphisms, insight can be drawn as to why certain cancer patients respond to and uptake MTX more successfully.en_US
dc.description.sponsorshipDepartment of Experimental and Clinical Therapeutics. Karmos Cancer Institute. Medical School. Wayne State University. Detroit, Michigan.
dc.publisherKalamazoo Collegeen_US
dc.relation.ispartofKalamazoo College Biology Senior Individualized Projects Collection
dc.relation.ispartofseriesSenior Individualized Projects. Biology;
dc.rightsU.S. copyright laws protect this material. Commercial use or distribution of this material is not permitted without prior written permission of the copyright holder.
dc.titlePolymorphism Determination of Mutations Found in the Human Reduced Folate Carrier Geneen_US
KCollege.Access.ContactIf you are not a current Kalamazoo College student, faculty, or staff member, email to request access to this thesis.

Files in this item


This item appears in the following Collection(s)

  • Biology Senior Individualized Projects [1550]
    This collection includes Senior Individualized Projects (SIP's) completed in the Biology Department. Abstracts are generally available to the public, but PDF files are available only to current Kalamazoo College students, faculty, and staff.

Show simple item record